The Microbiome as a New Industry: From Treatment to Disease Prediction and Personalized Medical Solutions
- Anastasia Kolomoiets
- May 11
- 4 min read
How does Ukraine enter the global market at the intersection of science, medicine, and business, and why is this important for the healthcare economy?
In the near future, we will increasingly hear that medicine is moving from treating diseases to managing health. Research is emerging every day that allows scientists and doctors to work not with the consequences of diseases, but with their early signals. And at the center of this transformation is data.
Thus, biological data is becoming the basis for personalized medical solutions. The microbiome analytics market is already estimated at approximately $1–2 billion. By the end of the decade, it may exceed $2–3 billion in the diagnostics segment alone, and in a broader sense reach over $10–20 billion within the human microbiome industry.
Ukraine, despite the military challenges, is part of these global changes: we are implementing research, new approaches to diagnostics are emerging, and a market for personalized medical solutions is being formed. Nadiya Boyko , Doctor of Biological Sciences, Professor, Head of the Department of Medical and Biological Disciplines of Uzhhorod National University, and co-founder of Ediens (Ukraine) and BioME (Bulgaria), told Mind more about how the microbiome has become a part of systemic medicine in Ukraine and the world, how it affects the medical economy, and what new industries it creates in the field of healthcare.
The growth rate of the microbiome analytics market remains high: an average of 10–30% annually, which puts it on a par with the most dynamic areas of biotechnology. The fastest growing segments are those that shape practical medicine: diagnostics, therapeutic solutions and personalized biotechnology.
One of the key drivers of this transformation, of course, has been the microbiome – a complex ecosystem of microorganisms that is increasingly seen as a source of data, diagnostics, and new business models.
For Ukraine, its research is no longer a scientific trend, but rather a stage in the creation of a new sector of the economy, in which 5 new medical industries are being formed at once :
Microbiome diagnostics.
Personalized biotherapy (pharmabiotics).
Mental health through the microbiome (psychobiotics).
BioData & AI Medicine.
Microbiome solutions in beauty and agriculture.
Global context: a new market at the intersection of biology, data and technology
In the US, the microbiome has long since moved beyond academic research and has become the core of a full-fledged industry at the intersection of medicine, biotechnology, and data science. Companies like Viome, DayTwo, and Second Genome are working with biological data that has become the basis for personalized medical solutions. And of course, this has a dramatic impact on commerce.
For us, this means moving from general advice like “eat right” to high-quality individual medical solutions. This is already evident in three practical areas:
Personalized nutrition – recommendations on which foods you need to eat to improve your weight, energy levels, and overall well-being.
Early risk assessment – understanding susceptibility to metabolic disorders, inflammation, or digestive problems before symptoms appear.
Individual approaches to restoring the body – from selecting a diet to supporting therapy.
Similar processes are taking place not only in the US. The market for microbiome solutions is actively forming in Europe and Asia.
In the EU, development is more regulated and gradual. Here, the microbiome is most often integrated into clinical medicine through university research, government programs, and collaboration with pharmaceutical companies. The emphasis is not so much on commercial services for the end user, but on the evidence base and medical protocols.
But in the UK and the Netherlands , for example, the microbiome is actively studied in the context of preventive medicine, gastroenterology, and immunology, as well as as part of large population health cohort studies.
In Asia, the approach is different, more applied and rapidly scalable. In China , Japan and South Korea, the microbiome is increasingly seen as part of the personalized nutrition, nutraceuticals and wellness industries. And there, commercial products are emerging more quickly, reaching the mass consumer market.
Ukraine: Future medicine is not about treatment, but about prediction
In Ukraine, the direction is just taking shape, but you can already see several new areas that are gradually emerging at the intersection of science, medicine, and business:
Microbiome diagnostics : Laboratories and research projects are emerging that analyze the microbiome as part of a patient's clinical assessment. This is the first step towards creating early diagnostic systems.
Pharmabiotics and personalized solutions . A new segment between pharmaceuticals and nutraceuticals is individual products that affect the microbiome. Ukrainian teams are already working in this direction, creating solutions for correcting the microbial balance.
Educational and clinical programs . Approaches are being developed to integrate the microbiome into clinical practice: from gastroenterology to mental health.
Multi-omics and data analytics . There is a growing demand for the analysis of complex biological data: genomics, metabolomics, microbiomics.
And for the microbiome to become part of systemic medicine , it is necessary:
large cohort studies;
data standardization;
clinical validation;
understandable business models.
Why has this become important now?
In the next 5–10 years, competition in medicine will not only be between hospitals or pharmaceutical companies, but also between systems that work better with data. And here a new reality emerges in which the winner is not the one who treats more, but the one who understands the risks earlier .
We are used to thinking of medicine as a system that responds to a problem that already exists. But the new logic is changing the very basis of this model: from reaction to prediction.
The microbiome is becoming one of the first tools that allows us to move from a “treat the disease” approach to “understand the risk before it occurs.” And this is changing not only clinical practice, but also the economics of healthcare.
In this new system, value is not created by the volume of treatment, but by the accuracy of the prognosis. And the countries that are the first to learn to work with biological data as infrastructure will occupy a fundamentally different position in the global medical economy.
Comments